Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Syed M. Abbas Rizvi"'
Publikováno v:
Cancers, Vol 3, Iss 2, Pp 1821-1843 (2011)
Evidence for the efficacy of targeted alpha therapy for the control of pancreatic cancer in preclinical models is reviewed. Results are given for in vitro pancreatic cancer cells and clusters and micro-metastatic cancer lesions in vivo. Two complemen
Externí odkaz:
https://doaj.org/article/7fd0b5d2741842438c8616788797f7fb
Autor:
Syed Amir Ashraf, Mitesh Patel, Amr S. Abu Lila, Syed M. Abbas Rizvi, Mohd Adnan, Ahmed N. Allam, Afrasim Moin, H.V. Gangadharappa
Publikováno v:
Drug Design, Development and Therapy. 14:5325-5336
Purpose The present work aimed at challenging the efficacy of natural gums, karaya and locust bean gum, as matrix-forming polymers for the formulation of sustained-release tablets of diltiazem, a model drug. Methods Central design composite was adopt
Publikováno v:
Orthopaedic Journal of Sports Medicine
Background: Arthroscopic capsular release has been shown to provide excellent short- and long-term outcomes in patients with idiopathic frozen shoulder. Some surgeons delay surgery in the belief that operating in the early stages of adhesive capsulit
Publikováno v:
Journal of Science and Medicine in Sport. 22:S11
Publikováno v:
Cancers, Vol 3, Iss 2, Pp 1821-1843 (2011)
Cancers
Volume 3
Issue 2
Pages: 1821-1843
Cancers
Volume 3
Issue 2
Pages: 1821-1843
Evidence for the efficacy of targeted alpha therapy for the control of pancreatic cancer in preclinical models is reviewed. Results are given for in vitro pancreatic cancer cells and clusters and micro-metastatic cancer lesions in vivo. Two complemen
Autor:
Chand Raja, Pamela J. Russell, Alfred Morgenstern, Christos Apostolidis, Julia Beretov, Syed M. Abbas Rizvi, Kamel Abbas, John H. Kearsley, Emma Song, Barry J. Allen
Publikováno v:
Scopus-Elsevier
Bevacizumab, a humanized anti-VEGF monoclonal antibody has shown promise in various clinical trials. We report the development and testing of Bi-213 (an alpha-emitting radionuclide) labeled bevacizumab for in vitro and in vivo studies using two diffe
Publikováno v:
Current Radiopharmaceuticalse. 1:240-250
This paper reviews the journey taken by the Centre for Experimental Radiation Oncology from bench to bedside in the development of targeted alpha therapy (TAT) for metastatic melanoma. The alpha-immunoconjugate (AIC) 213Bi-cDTPA-9.2.27 (AIC) has been
Publikováno v:
Physics in Medicine and Biology. 52:L15-L19
Targeted alpha therapy (TAT) is an emerging therapeutic modality, thought to be best suited to cancer micrometastases, leukaemia and lymphoma. TAT has not been indicated for solid tumours. However, several melanoma patients in a phase 1 clinical tria
Autor:
Ralph A. Reisfeld, Emma Song, Barry J. Allen, Syed M. Abbas Rizvi, Chand Raja, John H. Kearsley, Peter Graham, Alfred Morgenstern, Anja K. Bosserhoff, Christos Apostolidis, John F. Thompson, Helen Goldsmith
Publikováno v:
Cancer Biology & Therapy. 6:846-852
The aim is to assess toxicity and response of systemic alpha therapy for metastatic melanoma.This is an open-labelled Phase 1 dose escalation study to establish the effective dose of the alpha-immunoconjugate (213)Bi-cDTPA-9.2.27 mAb (AIC). Tools use
Pharmacokinetics and toxicity of 213Bi-labeled PAI2 in preclinical targeted alpha therapy for cancer
Autor:
Chand Raja, Martin W. Brechbiel, Syed M. Abbas Rizvi, Alfred Morgenstern, Chang F. Qu, Emma Song, Barry J. Allen, Christos Apostolidis
Publikováno v:
Cancer Biology & Therapy. 6:898-904
The plasminogen activator inhibitor type 2 (PAI2) when labelled with (213)Bi forms the (213)Bi-PAI2 alpha conjugate (AC). This AC has been shown to be efficacious in preclinical studies with breast, ovarian, prostate and pancreatic cancers. The objec